Field Force Effectiveness Project for IMS

IMS Health has recently announced a three-year agreement to provide Pfizer Inc. with data, analytics and advisory services. The collaboration is part of a comprehensive programme covering 23 countries that aims to enhance Pfizer's effectiveness in informing physicians about its innovative medicines.

Under the terms of the agreement, IMS will supply business intelligence and associated services to help Pfizer optimize the effectiveness of its field-based teams in Europe and Canada. Pfizer discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world's best-known over-the-counter brands.

'We are extremely pleased to broaden our relationship with Pfizer and to support them in such a significant programme' said Gilles Pajot, IMS executive vice president and president, IMS European Region. 'Our customized mix of data, analytics and advisory services enables us to apply IMS's business intelligence to help Pfizer make the best informed decisions in the field, at the point of customer contact.'

'We selected IMS to participate in this initiative for the depth, breadth and granularity of its market intelligence,' said Ian Read, president, Pfizer Europe and Canada. 'IMS's unique combination of experience, global reach and data assets will enable us to accurately assess and meet the diverse information needs of physicians in Europe and Canada.'

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas unless otherwise stated.

• IMS Health Inc
• All news